#USA #Chicago #Waud Capital #AOM Infusion #PromptCare

Waud Capital Partners Completes Sale of PromptCare Infusion to AOM Infusion

On November 11, 2026, Waud Capital Partners, a private equity firm focused on growth within the middle market, declared that it has successfully closed the sale of its portfolio company, PromptCare Infusion, to AOM Infusion. This deal was finalized on October 23, 2026, although specific financial terms of the transaction were not disclosed. The merger of AOM Infusion and PromptCare Infusion aims to establish one of the largest independent home and alternate-site infusion and specialty pharmacy platforms in the United States.

The Significance of the Transaction

PromptCare Infusion is renowned for providing vital home and alternate-site infusion therapy and specialty pharmacy services to patients dealing with complex, chronic, or rare medical conditions. The strategic combination with AOM Infusion creates a robust national platform with a focus on expanding healthcare access and delivering enhanced patient care. Both organizations share a history of substantial growth and development in this field, which positions them favorably for the future.

Waud Capital acquired PromptCare Infusion in 2021 as part of a broader strategy known as the Medication-Based Services initiative, which involved collaboration with seasoned executive Paul Jardina. During Waud Capital’s ownership, PromptCare Infusion saw impressive growth, with revenues increasing fivefold. This growth was attributed to both organic development and strategic acquisitions, including ARJ Infusion Services, PICC Lines Plus, and Coastal Infusion Services.

When Waud Capital stepped in, the PromptCare Infusion business was operating in 19 states. It has since expanded its reach to all 50 states and has more than doubled its pharmacy network to 10 locations. Additionally, the company successfully established 17 ambulatory infusion suites while expanding access to national payer networks and specialty pharmacy services. A dedicated commercial and business development organization was also built to further promote growth and outreach to patients in need.

Leadership and Vision for the Future

Tim Cremieux, a partner at Waud Capital, remarked on the partnership with PromptCare and its potential. “PromptCare Infusion is a clear example of Waud Capital's approach to developing a vision, collaborating with an experienced executive before we invest, and fostering a significant platform through organic growth alongside disciplined mergers and acquisitions,” he stated. Chris Graber, another partner with a focus on healthcare, expressed confidence in the transaction's future impact, saying, “Paul and the team have built an exceptional clinical organization, and we believe AOM is the right partner for its next chapter.”

Paul Jardina, Chairman, and CEO of PromptCare, shared his perspective on the collaboration with Waud Capital. He said, “Waud Capital was a true partner in every sense, sharing our vision, investing behind our people, and helping us build a platform that delivers exceptional care to patients with complex needs.” He added that both parties are proud of their achievements and optimistic about the future with AOM Infusion.

As Waud Capital steps aside from this segment of their business, they will continue to manage PromptCare's complex respiratory and enteral nutrition services. The firm remains committed to supporting the ongoing growth of these services in the healthcare industry.

About Waud Capital Partners

Waud Capital Partners is based in Chicago and was founded by Reeve B. Waud over 30 years ago. The firm is primarily focused on partnering with experienced management teams in two key sectors: healthcare and software technology. Since its inception in 1993, Waud Capital has successfully completed more than 500 investments, demonstrating a constant evolution and responsiveness to the market needs.

As the healthcare landscape continues to adapt and grow, this strategic sale represents a significant step for both PromptCare Infusion and AOM Infusion, promising enhanced care options and expanded reach for patients nationwide.